What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders

What happened: Krystal Biotech's VYJUVEK gene therapy for dystrophic epidermolysis bullosa has shown strong commercial traction, and the MHRA approved it in the U.K. Key numbers: Narrative projects $1.3 billion revenue and $772.0 million earnings by 2029, requiring 43.6% yearly revenue growth and a $530.5 million earnings increase from $241.5 million Why it matters: Strong VYJUVEK revenue and gross margins reinforce the core investment idea but do not change near term focus on European pricing outcomes as the key catalyst. Rising R&D and commercial costs could pressure earnings and margins. Market: +1.3% by next close ($331.61 on Oct 9), +33.9% YTD

Krystal Biotech's VYJUVEK gene therapy for dystrophic epidermolysis bullosa has shown strong commercial traction, and the MHRA approved it in the U.K.

Strong VYJUVEK revenue and gross margins reinforce the core investment idea but do not change near term focus on European pricing outcomes as the key catalyst. Rising R&D and commercial costs could pressure earnings and margins. Market: +1.3% by next close ($331.61 on Oct 9), +33.9% YTD